Squarepoint
PRME icon

Squarepoint’s Prime Medicine PRME Stock Holding History

Squarepoint’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Sell
88,029
-6,037
-6% -$20K ﹤0.01% 3746
2026
Q1 		$327K Sell
94,066
-123,976
-57% -$472K ﹤0.01% 3642
2025
Q4 		$757K Buy
218,042
+178,441
+451% +$794K ﹤0.01% 2852
2025
Q3 		$219K Buy
39,601
+3,775
+11% +$15.3K ﹤0.01% 3885
2025
Q2 		$88.5K Buy
+35,826
New +$55.2K ﹤0.01% 4201
2024
Q4 		– Sell
-124,369
Closed -$481K – 5405
2024
Q3 		$481K Buy
124,369
+60,908
+96% +$282K ﹤0.01% 3125
2024
Q2 		$326K Buy
63,461
+3,895
+7% +$23.6K ﹤0.01% 3381
2024
Q1 		$417K Sell
59,566
-11,957
-17% -$90.7K ﹤0.01% 3181
2023
Q4 		$634K Buy
71,523
+56,033
+362% +$432K ﹤0.01% 2839
2023
Q3 		$148K Buy
+15,490
New +$201K ﹤0.01% 3494

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Squarepoint's PRME Position: Q2 2026 in Review

Squarepoint reduced its Prime Medicine (PRME) stake by 6.4% in Q2 2026, selling an estimated $20K and leaving 88,029 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #3746.

Squarepoint first reported a position in PRME in Q3 2023 and has held it in 10 quarters since. The position peaked at $757K in Q4 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Squarepoint held 88,029 shares of Prime Medicine worth $325K as of Q2 2026.
  • Squarepoint sold 6,037 Prime Medicine shares in Q2 2026, an estimated $20K.
  • Prime Medicine made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3746 holding.
  • Squarepoint first reported a position in Prime Medicine in Q3 2023 and has held it in 10 quarters since.
  • Squarepoint's Prime Medicine position peaked at $757K in Q4 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.